Unknown NA INTERVENTIONAL 4-arm NCT01771042

The Effects of Weight Loss on Neuroadrenergic Function

Neuroadrenergic Dysfunction Along the Diabetes Continuum: Benefits of Weight Loss Within Different Strata of Metabolic Risk

Sponsor: Baker Heart Research Institute

Conditions Metabolic Syndrome Obesity Type 2 Diabetes

Interventions Dietary weight loss at 25% energy deficit

Updated 6 times since 2017 Last updated: Jan 16, 2013 Started: Apr 30, 2013 Primary completion: Apr 30, 2017 Completion: Apr 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Metabolic Syndrome and Obesity, this trial is ongoing. The trial is conducted by Baker Heart Research Institute and has accumulated 6 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status NA
Jun 2018 — Jan 2021 [monthly]

Unknown Status NA
May 2017 — Jun 2018 [monthly]

Unknown Status NA

Status: Not Yet Recruiting → Unknown Status

▶ Show 1 earlier version

Jan 2017 — May 2017 [monthly]

Not Yet Recruiting NA

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Baker Heart Research Institute

Data source: Baker Heart Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Melbourne, Australia